| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Restricted cash | 840 | 748 | ||
| Cash and cash equivalents | - | 0 | ||
| Trade accounts receivable, net | 4,435 | 4,934 | ||
| Inventories | 1,684 | 1,906 | ||
| Prepaid and other current assets | 959 | 1,382 | ||
| Total current assets | 7,918 | 8,970 | ||
| Property and equipment, gross | 532 | - | ||
| Less accumulated depreciation | 112 | - | ||
| Property and equipment, net | 420 | 424 | ||
| Operating lease right-of-use assets | 195 | 214 | ||
| Intangible asset, net (note 7) | 5,238 | 4,738 | ||
| Other noncurrent assets | 36 | 36 | ||
| Total assets | 13,807 | 14,382 | ||
| Accounts payable | 11,624 | 12,291 | ||
| Convertible notes-Baker Bros Notes | 18,509 | 14,746 | ||
| Convertible notes-Related Party | 983 | 35 | ||
| Convertible notes-Adjuvant Notes | 32,167 | 31,933 | ||
| Short term debt | 291 | 383 | ||
| Accrued expenses | 1,363 | 3,327 | ||
| Accrued compensation | 3,609 | 3,249 | ||
| Operating lease liabilities current | 124 | 124 | ||
| Derivative liabilities | 1,140 | 3 | ||
| Contingent liabilities - current (note 7) | 215 | 213 | ||
| Other current liabilities | 8,161 | 7,589 | ||
| Total current liabilities | 78,186 | 73,893 | ||
| Operating lease liabilities - noncurrent | 72 | 89 | ||
| Contingent liabilities - noncurrent (note 7) | 5,718 | 5,230 | ||
| Total liabilities | 83,976 | 79,212 | ||
| Convertible and redeemable preferred stock | 4,897 | 4,786 | ||
| Common stock, 0.0001 par value 3,000,000,000 shares authorized 123,956,354 and 113,356,354 shares issued and outstanding at september 30, 2025 and december 31, 2024, respectively | 12 | 12 | ||
| Additional paid-in capital | 831,816 | 831,424 | ||
| Accumulated other comprehensive loss | -6,718 | -2,556 | ||
| Accumulated deficit | -900,176 | -898,496 | ||
| Total stockholders deficit | -75,066 | -69,616 | ||
| Total liabilities, convertible and redeemable preferred stock and stockholders deficit | 13,807 | 14,382 | ||
Evofem Biosciences, Inc. (EVFM)
Evofem Biosciences, Inc. (EVFM)